4,5-Dihydro-1H-pyrazole derivatives with inhibitory nNOS activity in rat brain: Synthesis and structure - Activity relationships

Journal of Medicinal Chemistry

Volumn 47, Issue 23, 2004, Pages 5641-5650

  Camacho, M Encarnación ^a   León, Josefa ^b   Entrena, Antonio ^a   Velasco, Guillermo ^a   Carrión, M Dora ^a   Escames, Germaine ^b   Vivó, Antonio ^c   Acuña Castroviejo, Darío ^b   Gallo, Miguel A ^a   Espinosa, Antonio ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL COSTA DEL SOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 3 (2 AMINO 5 CHLOROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 ACETYL 3 (2 AMINO 5 METHOXYPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 ACETYL 3 (2 AMINOPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 BENZOYL 3 (2 AMINO 5 CHLOROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 BENZOYL 3 (2 AMINO 5 METHOXYPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 BENZOYL 3 (2 AMINOPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 BUTYRYL 3 (2 AMINO 5 CHLOROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 BUTYRYL 3 (2 AMINO 5 METHOXYPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 BUTYRYL 3 (2 AMINOPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 CYCLOBUTANECARBONYL 3 (2 AMINO 5 METHOXYPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 CYCLOHEXANECARBONYL 3 (2 AMINO 5 METHOXYPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 CYCLOPENTANECARBONYL 3 (2 AMINO 5 METHOXYPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 CYCLOPROPANECARBONYL 3 (2 AMINO 5 CHLOROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 CYCLOPROPANECARBONYL 3 (2 AMINO 5 METHOXYPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 CYCLOPROPANECARBONYL 3 (2 AMINOPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 PENTANOYL 3 (2 AMINO 5 METHOXYPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 PROPIONYL 3 (2 AMINO 5 CHLOROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 PROPIONYL 3 (2 AMINO 5 METHOXYPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 1 PROPIONYL 3 (2 AMINOPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; KYNURENINE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; MOLECULAR MODEL; NEUROPROTECTION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANILINE COMPOUNDS; ANIMALS; CORPUS STRIATUM; KYNURENINE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; PYRAZOLES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 7444245550     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0407714     Document Type: Article

References (59)

1. Danbolt, N. C. Glutamate uptake. Prog. Neurobiol. 2001, 65, 1-105.
2. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S. F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51, 7-61.
3. Herrling, P. L. Clinical implications of NMDA receptors. In The NMDA receptor; Colingridge, G. L.; Watkins, J. C., Eds.; Oxford: Oxford University Press, 1994; pp 376-394.
4. Meldrum, B.; Garthwaite, J. Excitatory amino acid neurotoxicity and neurodegenerative diseases. Trends Pharmacol. Sci. 1990, 11, 379-387.
5. Sattler, R.; Tymianski, M. Molecular mechanisms of calcium-dependent excitotoxicity. J. Mol. Med. 2000, 78, 3-13.
6. Schwarcz, R. Metabolism and function of brain kynurenines. Biochem. Soc. Trans. 1993, 21, 77-82.
7. Swartz, K. J.; During, M. J.; Freese, A.; Beal, M. F. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J. Neurosci. 1990, 10, 2965-2973.
8. Stone, T. W.; Perkins, M. N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in rat CNS. Eur. J. Pharmacol. 1981, 72, 411-412.
9. Meldrum, B. S.; Chapman, A. G. Competitive NMDA antagonist as drugs. In The NMDA receptor; Colingridge, G. L.; Watkins, J. C., Eds.; Oxford: Oxford University Press, 1994; pp 376-394.
10. Schwarcz, R.; Foster, A. C.; French, E. D.; Whetsell, W. O.; Köhler, C. Excitotoxic models for neurodegenerative disorders. Life Sci. 1984, 35, 19-32.
11. Beal, M. F.; Kowall, N. W.; Ellison, D. W.; Mazurek, M. F.; Swartz, K. J.; Martin, J. B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321, 168-171.
12. Kerr, S. J.; Armati, P. J.; Brew, B. J. Neurotoxicity of quinolinic acid in human brain cultures. J. Neurovirol. 1995, 1, 375-238.
13. Heyes, M. P.; Saito, K.; Lackner, A.; Wiley, A.; Achim, C. L.; Markey, S. P. Sources of the neurotoxin quinolinic acid in the brain of HIV-1 infected patients and retrovirus-infected macaques. FASEB J. 1988, 72, 881-896.
14. Santamaría, A.; Galvan-Arzate, S.; Lysy, V. Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport 2001, 12, 871-874.
15. Santamaría, A.; Jiménez-Capdevilla, M. E.; Camacho, A.; Rodríguez-Martínez, E.; Flores, A.; Galván-Arzate, S. In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. Neuroreport 2001, 12, 2693-2696.
16. Bordelon, Y. M.; Chesselet, M. F.; Nelson, D.; Welsch, F. Erecinska, M. Energetic disfunction in quinolinic acid-lesioned rat striatum. J. Neurochem. 1997, 69, 1629-1639.
17. Birch, P. J.; Grossman, C. J.; Hayes, A. G. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur. J. Pharmacol. 1988, 1, 85-87.
18. Parsons, C. G.; Danysz, W.; Quack, G.; Hartmann, S.; Lorenz, B.; Wollenburg, C.; Baran, L.; Przegalinski, E.; Kostowski, W.; Krzascik, P.; Chizh, B.; Headley, P. M. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 1997, 3, 1264-1275.
19. Foster, A. C.; Vezzani, A.; French, E. D.; Schwarcz, R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett. 1984, 3, 273-278.
20. Saito, K.; Nowak, T. S., Jr.; Markey, S. P.; Heyes, M. P. Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following tansient cerebral ischemia. J. Neurochem. 1993, 60, 180-182.
21. Moroni, F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur. J. Pharmacol. 1999, 375, 87-100.
22. Kemp, J. A.; Foster, A. C.; Leeson, P. D.; Priestly, T.; Tridgett, R.; Iversen L. L.; Woodruff, G. N. 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 6547-6550.
23. (a) McNamara, D.; Smith, E. C.; Calligaro, D. O.; O'Malley, P. J.; McQuaid, L. A.; Dingledine, R. 5,7-Dichlorokynurenic acid, a potent and selective competitive antagonist of the glycine site on NMDA receptors. Neurosci Lett. 1990, 120, 17-20.
24. (b) Baron, B. M.; Harrison, B. L.; Miller, F. P.; McDonald, I. A.; Salituro, F. G.; Schmidt, C. J.; Sorensen, S. M.; White, H. S.; Palfreyman, M. G. Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site. Mol. Pharmacol. 1990, 38, 554-561.
25. Takano, K.; Tatlisumak, T.; Formato, J. E.; Carano, R. A.; Bergmann, A. G.; Pullan, L. M.; Bare, T. M.; Sotak, C. H.; Fisher, M. Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. Stroke 1997, 28, 1255-1262.
26. Stone, T. W.; Darlington, L. G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discovery 2002, 1, 609-620.
27. a) Stone, T. W. Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin. Investig. Drugs 2001, 10, 633-645.
28. (b) Stone, T. W. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog. Neurobiol. 2001, 64, 185-218.
29. Moroni, F.; Russi, P.; Gallo-Mezo, M. A.; Moneti, G.; Pellicciari, R. Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine. J. Neurochem. 1991, 57, 1630-1635.
30. (a) Connick, J. H.; Heywood, G. C.; Sills, G. J.; Thompson, G. G.; Brodie, M. J.; Stone, T. W. Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gen. Pharmacol. 1992, 23, 235-239.
31. (b) Russi, P.; Alesiani, M.; Lombardi, G.; Davolio, P.; Pellicciari, R.; Moroni, F. Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J. Neurochem. 1992, 59, 2076-2080.
32. Schwarcz, R.; Pellicciari, R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 2002, 303, 1-10.
33. Moncada, S.; Palmer, R. M. J.; Higgs, E. A. Nitric Oxide: Physiology, Pathophysiology, and Pharmacology. Pharmacol. Rev. 1991, 43, 109-142.
34. Mayer, B. M.; John, M.; Bohme, E. Purification of a Ca2+/Calmodulin- Dependent Nitric Oxide Synthase from Porcine Cerebellum: Cofactor Role of Tetrahydrobiopterin. FEBS. Lett. 1990, 277, 215-219.
35. Pollock, J. S.; Förstermann, U.; Mitchel, J. A.; Warner, T. D.; Schmidt, H. H.; Nakane, M.; Murad, F. Purification and Characterization of Particulate Endothelium Derived Relaxing Factor Synthase from Cultured and Native Bovine Aortic Endothelial Cells. Proc. Natl. Acad. Sci. U.S.A., 1991, 88, 10480-10484.
36. Stuehr, D. J.; Cho, H. J.; Kwon, N. S.; Weise, M. F.; Nathan, C. F. Purification and Characterization of the Cytokine-Induced Macrophage Nitric Oxide Synthase: a FAD-Containing and FMN-Containing Flavoproteins. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 7773-7777.
37. Hevel, J. M.; White, K. A.; Marletta, M. A. Purification of the Inducible Murine Macrophage Nitric Oxide Synthase. Identification as a Flavoprotein. J. Biol. Chem. 1991, 266, 22789-22791.
38. Knowles, R. G.; Palacios, M.; Palmer, M. R. J.; Moncada, S. Formation of Nitric Oxide from L-Arginine in the Central Nervous System: A Transduction Mechanism for Stimulation of the Soluble Guanylate Cyclase. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 5159-5162.
39. McCall, T. B.; Boughton-Smith, N. K.; Palmer, R. M. J.; Whittle, B. J. R.; Moncada, S. Synthesis of Nitric Oxide from L-arginine by Neutrophils: Release and Interaction with Superoxide Anion. Biochem. J. 1989, 267, 293-296.
40. Pozo, D., Osuna, C., Calvo, J. R., Guerrero, J. M.: Produccion de Oxido Nitrico y Su Modulation en el Sistema Inmune y el Sistema Nervioso. Archivos de Neurociencias. Arch. Neurocien. 1998, 3, 84-94.
41. Smith, M. A.; Vasak, M.; Knipp, M.; Castellani, R. J.; Perry, G. Dimethylargininase, a nitric oxide protein, in Alzheimer disease. Free Radical Biol. Med. 1998, 25, 898-902.
42. Yew, D. T.; Wong, H. W.; Li, W. P.; Lai, H. W.; Yu, W. H. Nitric oxide synthase in different areas of normal aged and Alzheimer's brains. Neuroscience 1999, 89, 675-686.
43. Wong, N. K.; Strong, M. J. Nitric oxide synthase expression in cervical spinal cord in sporadic amyotrophic lateral sclerosis. Eur. J. Cell. Biol. 1998, 77, 338-343.
44. Norris, P. J.; Waldvogel, H. J.; Faull, R. L.; Love, D. R.; Emson, P. C. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease. Neuroscience 1996, 4, 1037-1047.
45. Leon, J.; Vives, F.; Crespo, E.; Camacho, E.; Espinosa, A., Gallo, M. A.; Escames, G.; Acuña-Castroviejo, D. Modification of Nitric Oxide Synthase Activity and Neuronal Response in Rat Striatum by Melatonin and Kynurenine Derivates. J. Neuroendocrinol. 1998, 10, 297-302.
46. Camacho, E.; León, J.; Carrión, A.; Entrena, A.; Escames, G.; Khaldy, H.; Acuña-Castroviejo, D.; Gallo, M. A.; Espinosa, A. Inhibition of nNOS Activity in Rat Brain by Synthetic Kynurenines: Structure-Activity Dependence. J. Med. Chem. 2002, 45, 263-274.
47. Fürstner, A.; Jumbam, D.; Scidel, G. Syntheses of zindoxifene and analogues by titanium-induced oxo-amide cupling. Chem. Ber. 1994, 727, 1125-1130.
48. Shen, W.; Coburn, C. A.; Bornmann, W. G.; Danishefsky, S. J. Concise total syntheses of dl-camptothecin and related anticancer drugs. J. Org. Chem. 1993, 58, 611-617.
49. Clark, M.; Cramer, R. D.; Van Opdenbosch, N. Validation of the general-purpose tripos 5.2 force-field. J. Comput. Chem. 1989, 70, 982-1012.
50. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Gill, P. M. W.; Jonson, B. G.; Robb, M. A.; Cheseman, J. R.; Keith, T.; Peterson, G. A.; Montgomery, J. A.; Raghavachari, K.; Al-Laham, M. A.; Zakrzewski, V. G.; Ortiz, J. V.; Foresman, J. B.; Cioslowski, J.; Stefanov, B. B.; Nanayakkara, A.; Challacombe, M.; Peng, C. Y.; Ayala, P. Y.; Chen, W.; Wong, M. W.; Andres, J. L.; Replogle, E. S.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Binkley, J. S.; Defrees, D. J.; Baker, J.; Stewart, J. P.; Head-Gordon, M.; Gonzalez, C.; Pople, J. A. Gaussian, Inc., Pittsburgh, PA, 1995.
51. SYBYL Molecular Modeling Software, Tripos Inc. 1699 S. Hanley Rd, St. Louis, MO 63144-2913; www.tripos.com.
52. Powell, M. J. D. Restart Procedures for the Conjugate Gradient Method. Math. Program. 1997, 12, 241-254.
53. (a) Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity. A Rapid Access to Atomic Charges. Tetrahedron, 1980, 36, 3219-3228.
54. (b) Marsili, M.; Gasteiger, J. Charge Distributions from Molecular Topology and Pi-orbital Electronegativity. Croat. Chem. Acta. 1980, 53, 601-614.
55. (c) Gasteiger, J.; Marsili, M. Prediction of Proton Magnetic Resonance Shifts: The Dependence on Hydrogen Charges Obtained by Iterative Partial Equalization of Orbital Electronegativity. Org. Magn. Reson. 1981, 15, 353-360.
56. Lowry, O. H.; Rosebroigh N. J.; Farr, A. S.; Randall, R. J. Protein measurement with the Folin Phenol reagent. J. Biol. Chem. 1951, 193, 265-267.
57. Bredt, D. S.; Snyder, S. H. Isolation of Nitric Oxide Synthethase, a Calmodulin Requiring Enzyme. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 682.
58. Carpenedo, R.; Chiarugi, A.; Russi, P.; Lombardi, G.; Carla, V.; Pellicciari, R.; Mattoli, L.; Moroni, F. Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience 1994, 61, 237-243.
59. Heyes, M. P.; Quearry, B. J. Quantification of 3-hydroxykynurenine in brain by high-perfomance liquid chromatography and electrochemical detection. J. Cromatogr. 1988, 428, 340-344.